Gilead Sciences has announced an agreement to acquire Tubulis, a German biotechnology startup, in a transaction valued at potentially $5 billion. This marks Gilead’s third acquisition in less than two months, signaling a major push to bolster its oncology pipeline.
Key terms and objectives of the deal include:
-
Financial Structure: Gilead will pay $3.15 billion upfront in cash. An additional $1.85 billion may be paid out upon the achievement of specific future development milestones.
-
Next-Generation ADC Technology: Tubulis specializes in antibody-drug conjugates (ADCs), a class of targeted therapies that pair a targeting molecule with a cancer-killing toxin. Tubulis’ unique approach utilizes specialized chemical linkers designed to reduce toxicity and overcome drug resistance in malignant tumors.
-
Enriching the Product Pipeline: Through this acquisition, Gilead gains two promising drug candidates, TUB-040 (currently in testing for ovarian cancer) and TUB-030. Both are expected to differentiate themselves from current ADC therapies on the market.
-
Long-term Strategy: Historically recognized for its HIV franchise, Gilead has invested billions over the past decade to establish an oncology business. The Tubulis acquisition not only fills gaps in its developmental roadmap but also secures a dedicated R&D hub in Munich, Germany.
Analysts view this as a strategically sound move to secure a differentiated ADC platform, ensuring Gilead remains competitive as targeted therapies become a staple in modern cancer treatment.
Source: https://www-biopharmadive-com.translate.goog/news/gilead-tubulis-acquire-deal-adc-cancer/816823/?_x_tr_sl=en&_x_tr_tl=vi&_x_tr_hl=vi&_x_tr_pto=tc